Pediatric Patient Considerations During Dose Development




Register Now
Date: Tuesday, December 12, 2017
Time: 2pm EST | 7pm GMT
Overview

Pediatric clinical trials are becoming more prevalent and are now typically mandatory within clinical development plans. However pediatric populations present significant development challenges related to dose form design. Pediatric patients experience unique differences from the adult population in pharmacokinetic parameters and, consequently, require individualized dosing. Additionally, dose forms suitable for adult populations often are not acceptable to children, due to swallowability and taste masking.  The absence of an available pediatric dosage forms can lead to increased potential for dosing errors or nonadherence. Therefore, specific dosing guidelines and useful dosage forms for pediatric patients need to be developed to optimize therapeutic efficacy and limit and prevent serious adverse side effects. This webinar will focus on several key considerations for developing a new drug for pediatric patients including: 

  • Overview of specific pediatric population challenges and needs
  • Advances in pediatric drug development
  • Discussion of pediatric-centric dose forms
  • Case studies of real-world pediatric medications

Presenters: 

Rachel Meyers, PharmD, BCPS, BCPPS

Rachel Meyers is a Clinical Associate Professor at the Ernest Mario School of Pharmacy at Rutgers University, and the Pediatric Clinical Pharmacist at Saint Barnabas Medical Center in Livingston, New Jersey.  Dr. Meyers completed her undergraduate degree at the University of Mary Washington and her Doctor of Pharmacy degree at the University of Connecticut.   She completed a PGY-1 residency at the University of Wisconsin Hospital and Clinics in Madison, Wisconsin, and her PGY-2 residency in Pediatric Pharmacotherapy at the University of North Carolina Children’s Hospital in Chapel Hill, North Carolina.  Dr. Meyers provides both didactic and experiential education in pediatric pharmacotherapy for pharmacy students and residents.  She practices in the Pediatric Intensive Care Unit and General Pediatric Unit at Saint Barnabas Medical Center.  She is actively involved in the Pediatric Pharmacy Advocacy Group and the American Society of Health-System Pharmacists.  Her research interests include pediatric infectious disease, pediatric hypertension, and dosage forms and measuring devices for children.

Cornell Stamoran Ph.D., Vice President of Corporate Strategy at Catalent Pharma Solutions

Cornell Stamoran has spent nearly 25 years engaged with the health care industry, including 20 years’ in advanced drug delivery. Cornell has been fortunate to experience the realities of patient adherence and outcomes enhancement from almost every stakeholder perspective.  Cornell has gained frontline experience on the realities of patient adherence and outcomes enhancement, from direct engagement with retail and hospital pharmacists; medical professionals; specialty pharmacies and clinics; PBMs; and payors.  Cornell has directly participated in the development of drug design-enabled adherence and outcomes enhancement strategies for more than 150 branded drugs over the last 10 years. During his 20 year tenure at Catalent, Mr. Stamoran has held many roles across a variety of disciplines, including financial and tax accounting; SEC reporting and financial planning; strategic business and technology planning; sales/business development; market intelligence; corporate development; marketing and branding; innovation; and public and investor relations. He holds several professional certifications, and is a graduate of the University of Michigan.

Register Now
Date: Tuesday, December 12, 2017
Time: 2pm EST | 7pm GMT